The average P/S ratio for SNY's competitors is 4.21, providing a benchmark for relative valuation. Sanofi SA Corp (SNY) exhibits a P/S ratio of 2.68, which is -36.39% above the industry average. Given its robust revenue growth of %, this premium appearsunsustainable.